Verge launches Phase 1 trial to test PIKfyve inhibitor therapy in ALS
Verge Genomics has launched a proof-of-concept trial to test whether VRG50635, its oral PIKfyve inhibitor therapy, can be used…
Articles by Andrea Lobo, PhD
Coya aligns with FDA on plans for developing COYA 302 for ALS
After two meetings with the U.S. Food and Drug Administration (FDA), Coya Therapeutics says it’s received constructive feedback —…
Arbor, 4DMT to develop novel gene therapies for ALS, other diseases
Arbor Biotechnologies and 4DMT — two U.S. companies working in next-generation genetic medicines — have established a strategic…
FDA, PharmAust to meet over plans for Phase 2/3 trial of monepantel
PharmAust announced that it soon will engage with U.S. Food and Drug Administration (FDA) regulators regarding development plans…
NurOwn and its exosomes given patents in Europe, Australia, Israel
BrainStorm Cell Therapeutics has received patents in Europe, Australia, and Israel covering the use of investigational NurOwn…
Tuberculosis vaccine screening links T-cell response to ALS risk
People with negative responses to a tuberculin skin test a few years after being vaccinated against tuberculosis had a significant,…
PrimeC can significantly slow ALS progression, PARADIGM trial finds
People with amyotrophic lateral sclerosis (ALS) given PrimeC in the PARADIGM Phase 2b trial — and who did not…
Final part of Phase 1 trial to test prosetin in ALS patients
Health Canada has cleared ProJenX to open the third part of its ongoing Phase 1 clinical trial and begin…
Blink reflex test may be biomarker to diagnose, monitor ALS: Study
A test that assesses the electrical activity associated with blinking may help speed the diagnosis of amyotrophic lateral…
ALS research center planned to open at Vanderbilt University
A neuroscientist with a specialty in amyotrophic lateral sclerosis (ALS) is joining the faculty at Vanderbilt University Medical Center…